[theold]

EyePoint Pharmaceuticals’ partner has received Chinese approval for an implant to treat a form of eye inflammation, becoming the first company to get a nod in the country based entirely on real-world data. Ocumension Therapeutics paid an initial $1.75 million to access EyePoint’s technology in 2018.

https://www.fiercepharma.com/pharma/firs...world-data